FIELD: biotechnology.
SUBSTANCE: methods for the treatment of B-cellular lymphoma are proposed. In this case, the method includes immunotherapy with genetically modified T-cells aimed at CD19 in a combination with 4-1BB agonist (CD137).
EFFECT: invention can be used for efficient treatment of B-cellular lymphoma, including diffuse large-cell B-cellular lymphoma.
47 cl, 14 dwg, 9 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED IMMUNE CELLS WITH DOUBLE shRNA AND COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2793922C2 |
| DEVICES AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | 2018 |
|
RU2795984C2 |
| CHIMERIC RECEPTORS CONTAINING TRAF-6-INDUCING DOMAINS AND COMPOSITIONS AND METHODS RELATED TO THEM | 2016 |
|
RU2773159C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND PROMOTER | 2015 |
|
RU2799573C2 |
| LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND-PROMOTER | 2015 |
|
RU2708311C2 |
| METHODS FOR MODULATING CART-CELLS | 2017 |
|
RU2774232C2 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| METHODS AND COMPOSITIONS FOR OBTAINING GENETICALLY ENGINEERED CELLS | 2018 |
|
RU2795454C2 |
